As afatinib irreversibly inhibits EGFR, HER2 as well as HER4 and consequently also HER3 by inhibiting its dimerization partners, a more pronounced therapeutic benefit with afatinib might be expected in patients with HNSCC experiencing cetuximab resistance. Here, ERBB4 is linked to head and neck squamous cell carcinoma.